Kenalog and Injection site inflammation - a phase IV clinical study of FDA data

Summary:

Injection site inflammation is reported as a side effect among people who take Kenalog (triamcinolone acetonide), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Buspar, and have Diabetic retinopathy.

The phase IV clinical study analyzes which people have Injection site inflammation when taking Kenalog. It is created by eHealthMe based on reports of 10,533 people who have side effects when taking Kenalog from the FDA, and is updated regularly.

What is Kenalog?

Kenalog has active ingredients of triamcinolone acetonide. It is often used in pain. eHealthMe is studying from 10,692 Kenalog users. Check the latest studies of Kenalog.

What is Injection site inflammation?

Injection site inflammation is found to be associated with 409 drugs and 430 conditions by eHealthMe. Check the latest studies of Injection site inflammation.

On Jul, 04, 2026

10,533 people reported to have side effects when taking Kenalog.
Among them, 19 people (0.18%) have Injection site inflammation.

Could Kenalog cause Injection site inflammation?

Among these 19 people:

How long have people been on Kenalog when they have Injection site inflammation? *

What is the gender of people who have Injection site inflammation when taking Kenalog? *

female: 100 %
male: 0.0 %

What is the age of people who have Injection site inflammation when taking Kenalog? *

What are other drugs people take besides Kenalog? *

What are other side effects people have besides Injection site inflammation? *

Injection Site Swelling: 11 people, 57.89%
Intraocular Pressure Increased: 5 people, 26.32%
Vision Blurred: 4 people, 21.05%
Arthropathy: 2 people, 10.53%
Skin Blushing/flushing (a sudden reddening of the face, neck): 2 people, 10.53%
Oedema Peripheral (superficial swelling): 2 people, 10.53%
Injection Site Necrosis (death of body tissue at injection site): 1 person, 5.26%
Back Pain: 1 person, 5.26%
Blindness Transient (sudden loss of vision): 1 person, 5.26%
Ear Haemorrhage (bleeding from ear): 1 person, 5.26%

What are the existing conditions these people have? *

Venous Occlusion (the blocking of venous return): 5 people, 26.32%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 5 people, 26.32%
Rashes (redness): 2 people, 10.53%
Osteoporosis (bones weak and more likely to break): 1 person, 5.26%
Cyst (a closed sac): 1 person, 5.26%
Bursitis (inflammation of a bursa, typically one in the knee, elbow, or shoulder): 1 person, 5.26%
Back Pain: 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Kenalog and have Injection site inflammation?

- Check whether Injection site inflammation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kenalog:

Kenalog (10,692 reports)

Browse all side effects of Kenalog:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site inflammation:

Injection site inflammation (409 drugs)

Browse all the conditions that are associated with Injection site inflammation:

Injection site inflammation (430 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on triamcinolone acetonide (the active ingredients of Kenalog) and Kenalog (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.